

Please type a plus sign (+) inside this box →



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/961,376
				Filing Date	September 25, 2001
				First Named Inventor	RUBEN et al.
				Group Art Unit	1646
				Examiner Name	P. Mertz
Sheet	1	of	1	Attorney Docket Number	PF524P1

RECEIVED
 NOV 05 2003
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
PM	AA	5,969,102		St Jude Children's Research Hospital	10-19-1999

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
PM	AB	WO	98/39361		St Jude Children's Research Hospital	09-11-1998
	AC	WO	98/18921	A1	Human Genome Sciences	05-07-1998
	AD	WO	00/40716		Zymogenetics, Inc.	07-13-2000
	AE	WO	00/50597	A2	Human Genome Sciences	08-31-2000
	AF	WO	00/58362	A1	Human Genome Sciences	10-05-2000
✓	AG	WO	00/67034		Immunex Corp.	09-11-2000

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
PM	AH	VON BULOW et al., NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily. (1997) Science 278:138-141.			
	AI	GROOM et al., Association of BAFF/BlyS overexpression and altered B cells differentiation with Sjogren's Syndrome. J Clin. Invest. (2002) 109:59-68.			
	AJ	ZHANG et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus. J. Immunol. (2001) 166:6-10.			
	AK	CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, Arthritis Rheum. (2001) 44:1313-1319.			
	AL	MARRIETTE et al., A Role for B Lymphocyte Stimulator (TALL-1, BAFF, THANK, zTNF4) in Sjogren's Syndrome. 65 th Annual American College of Rheumatology Scientific Meeting, Nov. 2001.			
	AM	VAUX et al., The Buzz about BAFF. J Clin. Invest. (2002) 109:17-18.			
✓	AN	GROSS et al., TACI and BCMA are Receptors For a TNF Homologue Implicated In B-cell Autoimmune Disease. Nature (2000) 404:995-999.			

Examiner Signature	Penna Mertz	Date Considered	4/12/04
--------------------	-------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.